New research suggests that people who come off blockbuster weight-loss injections like Mounjaro or Wegovy may regain lost weight much more quickly than those who stop conventional diet and exercise plans.
Published data in a prominent health publication shows that while obese people often shed substantial amounts of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month once they quit.
"People buying these treatments need to be informed of the risk of rapid weight regain when the medication ends," cautioned expert Dr. Susan Jebb.
Such speed of regain means a reversion to pre-treatment weight in about one and a half years.
Comparing Therapies
The study, which examined dozens of studies involving over 9,000 of participants, compared the results of the injectable medications with conventional dieting.
The team emphasize that people who shed pounds through dieting usually see a less rapid creep back—around 100 grams monthly—once they finish.
Explaining the Quick Rebound
Experts propose the mechanism of the injections is key to understanding the heightened regain.
The injections imitate a body's own chemical called GLP-1, which moderates appetite.
"Sustained high doses of GLP-1 levels far above than normal may cause the body to produce less of its own natural GLP-1, and could lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication leads to appetite is no longer kept in check, making overeating far more likely."
A Chronic Issue?
The NHS suggest the jabs for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Professionals argue that, considering the likelihood of relapse, the treatment might need to be long-term.
This perspective is echoed by pharmaceutical companies, who say that the findings "highlight the long-term character of excess weight," comparing it to managing conditions like hypertension.
User Experiences
People who have discontinued the jabs report a intense resurgence of cravings.
"I experienced a trigger activating and you become ravenous," described one woman.
This challenge is exacerbated if patients have not established sustainable dietary or behavioural modifications during therapy.
Widespread Use
Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the past year, with desire continuing to grow.
- Adoption is greater among women than men.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the drugs through private prescriptions rather than public health services.
Ultimately, clinicians stress that while GLP-1 drugs are effective tools for weight loss, they are not a magic solution and lasting health benefits relies on integrated lifestyle management.
